Our portfolio has the potential for sustainable revenue beginning 2027, with built-in life cycle management, risk diversification and continued leadership in retinal innovation Net sales (USD) 2027 2028 2029 2030 2031 2032 Tarcocimab KSI-501 KSI-101 Net Sales Potential of Kodiak Clinical Portfolio (Illustrative) Tarcocimab launch in DR, wet AMD and RVO Potential launch of KSI-501 Potential launch of KSI-101 in MESI Potential for strong immediacy and best durability Mainstay Biologic Potential for best efficacy and strong immediacy and best durability “Next gen” product to fast follow tarcocimab Mainstay Biologic Greenfield market Safe, potent, local biologic in a greenfield market segment of high unmet need Kodiak’s assets are proprietary and wholly-owned. We have the flexibility in our commercialization decisions to support adoption of our products in the marketplace. 6